Immunotherapy




Because of the novel mechanisms of action of immunotherapies, extended treatment period, and unique toxicities, cancer treatment with immunotherapy warrants special consideration from a survivorship standpoint, suggested Katy K. Tsai, MD, Clinical Instructor, Division of Hematology/Oncology, University of California, San Francisco (UCSF), at the 2018 Cancer Survivorship Symposium. Read Article ›






Advances in immunotherapy are benefiting increasing numbers of patients living with cancer. Since 2011, the FDA approved 15 immunotherapies in oncology, including 5 immunotherapy drugs in 2016. Read Article ›

Page 4 of 5

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: